The relief rally arrived with substance: Wall Street ripped Monday on the US–Iran deal, the S&P 500 closing +1.65% at 7,554 and the Nasdaq +3.07% at 26,684, with semis and SpaceX’s record second-day surge (+$412bn) leading. But the follow-through is faltering this morning. The BOJ hiked to a 31-year high of 1.00% (7–1 vote, governor absent) and flagged more to come; China’s economy stalled — retail sales fell for the first time in three years and property stocks tumbled to pre-stimulus levels — and Asian equities pared gains. Crude steadied near $80 after its slump, but Trump and European allies are now openly at odds over how quickly Hormuz can actually reopen, and the largest tanker operator warns flows will take weeks. All eyes turn to Warsh’s first Fed decision tomorrow, where economists are increasingly betting on a hawkish hold or even a hike, before Friday’s signing ceremony in Switzerland.
Europe/Rome 06:00 · US–Iran signing Fri · allies split on Hormuz · BOJ hikes to 1% · China stalls · Wall St at records Mon
▶ Listen · audio briefing (~5 min)
Snapshot is Monday 15 June’s US/UK closes from the live Bloomberg ticker read this morning — the deal rally is now in the cash prints (S&P +1.65%, Nasdaq +3.07%). Asian cash markets are open and softer this morning as the BOJ hike and weak China data take the shine off; commodities, the 10-year and FX show the live overnight move. Swing factors into the European and US opens: the Warsh Fed decision tomorrow, the G7 at Évian (day 2), and the Friday Hormuz signing and its contested logistics.
Top of the morning
Wall Street rallied hard on the deal — but Asia’s follow-through is faltering this morning
The US–Iran agreement turned into a full risk-on session on Monday: the S&P 500 jumped 1.65% to 7,554 and the Nasdaq 3.07% to 26,684, both at or near records, with SpaceX’s blockbuster debut still feeding the tape. Overnight the mood cooled. The BOJ hike, a renewed slump in Chinese activity and property, and questions over how fast Hormuz reopens left Asian equities mixed-to-lower and the yen choppy. The 10-year edged up to ~4.48% as the war premium kept unwinding and rate-cut hopes faded ahead of Warsh’s Fed.
BOJ raises rates to a 31-year high of 1.00% and signals it is not done
The Bank of Japan lifted its policy rate 25bp to 1.00% — the highest since 1995 — in a 7–1 vote, with board member Asada dissenting and Governor Ueda absent. It also said it will hold bond purchases steady at about ¥2tn a month from April 2027, effectively ending the taper, and pointed to further normalisation ahead. The yen pared its initial gains versus the dollar as traders judged the hawkish-but-gradual message broadly as expected; Japanese yields pushed higher.
US and allies split on Hormuz; the largest tanker operator says flows take “weeks”
Trump insists the Strait of Hormuz will reopen by Friday’s signing, but European partners are visibly less confident, and the boss of Mitsui OSK Lines — the world’s biggest tanker operator — cautioned that owners need time to rebuild confidence before sending ships back, so physical crude flows could take weeks to normalise. Crude held near $80 as Morgan Stanley cut its oil forecasts on the revived supply outlook; the war premium is draining, but slowly. Separately, the administration is said to be weighing a $300bn fund for Iran tied to the deal’s “performance.”
May data undercut the recovery narrative: retail sales declined for the first time in more than three years, fixed-asset investment deepened its slump, and home prices fell at a faster pace. Chinese property stocks tumbled back to pre-2024-stimulus levels, and refiners slashed run rates after crude imports plunged. The soft print revives the case for fresh stimulus and sits awkwardly against Beijing’s parallel pushes — a dollar-rivalling cross-border digital-payments system and a fight with Indonesia over $50bn of threatened nickel investment.
Warsh’s first Fed decision lands tomorrow — and economists are leaning hawkish
The FOMC’s two-day meeting opens today, with Kevin Warsh chairing his first decision Wednesday alongside a fresh dot plot and May retail sales. FT reports economists increasingly bet on higher rates, with inflation still above target and the energy-relief from the Iran deal only partly offsetting; the focus is Warsh’s inaugural press conference and how forcefully he signals the path. The BOE follows Thursday (hold at 3.75% expected despite inflation anxiety), after the BOJ’s hike completes a heavy central-bank week.
The AI financing machine keeps roaring: Nvidia’s $25bn bond, SpaceX’s surge, Bain’s windfall
Nvidia launched its first bond sale since 2021, seeking over $25bn and drawing roughly $85bn of orders at the peak — the latest test of investor appetite amid a deluge of AI-sector borrowing. SpaceX added $412bn of value in a second day of trading after its record IPO, and FT reports the AI boom is delivering private equity’s biggest-ever windfalls, with Bain Capital set to pocket a ~$15bn gain on chipmaker Kioxia. The buildout is real; the question, as ever, is the funding plumbing — a record ~$8tn still sits in money-market funds.
Geopolitics: EU opens Ukraine accession talks, fresh UK Russia sanctions, Netanyahu under fire
The EU formally began membership talks with Ukraine after Hungary’s new leadership dropped its veto, with Moldova moving in parallel — a symbolic milestone amid the wider de-escalation. The UK is set to announce new Russia sanctions and Ukraine energy support, and the EU said China trained Russian troops for the war. Netanyahu faces a domestic backlash across the political spectrum over the US–Iran deal, while at the G7 in Évian Trump hailed the agreement even as divisions with Tehran on sequencing persist. In media, Murdoch’s Fox agreed to buy Roku for $22bn.
FT portfolio signal · tied to your holdings
What FT flagged for your book
Macro / regime read. FT frames the open as a possible “peace dividend” — an end to the Iran war boosting confidence in global growth and corporate earnings — but plants the same two yellow flags as the tape. First, the oil relief is slower than priced: FT’s lead shipping story has the largest tanker operator warning Hormuz flows take weeks, echoing the “backlog could take weeks to clear” line and Trump’s split with allies on timing. Second, the rate path is tilting hawkish: FT’s curtain-raiser has economists betting on higher rates as Warsh takes the Fed, with inflation still above target into Wednesday’s dot plot. A subtler regime flag worth your attention: FT’s “the price of risk is falling in a more dangerous world” — capital pouring into insurance for high returns and low volatility, with insiders worried about mispricing. That is textbook late-cycle complacency: spreads and vol compressing into a still-fragile backdrop. No fresh severe trigger, so war-chest deployment rules stay sheathed — but a hawkish-Fed, slow-oil, complacent-vol mix keeps the regime defensive-to-neutral even as the rally has legs.
AI capex & semiconductors (theme — your semis/cloud shelf) · read-through to Broadcom, ASML, Microsoft, Alphabet, Amazon. FT’s “AI fuels private equity’s biggest-ever windfalls” (Bain’s ~$15bn on Kioxia) and Nvidia’s $25bn bond underline a still-voracious compute build — but increasingly debt-funded. The signal for your compute/cloud shelf stays durable end-demand; the watch-item is the funding source, with the AI complex now leaning on a bond and private-credit deluge rather than only cash flow.
European autos / China competition (theme). FT reports hedge funds are betting against European carmakers’ debt and equity on Chinese-competition fears, with tens of billions of euros of value already wiped off the sector. Not a held name, but a useful read on where the “China overcapacity” squeeze is biting next — relevant to any industrials/autos exposure and to the broader China-demand picture behind Caterpillar / Deere.
Healthcare (sector — your defensive sleeve) · quiet on your names. No GLP-1 (Novo Nordisk / Eli Lilly), UnitedHealth, Vertex, Thermo Fisher or Intuitive Surgical single-name items today. The health thread is policy/tech-led — FT’s scrutiny of Palantir’s claimed NHS productivity gains (driven by a handful of hospitals) and the DR Congo Ebola outbreak now topping 800 cases — not a catalyst for held names.
Payments / consumer / Berkshire — quiet. No Visa, Mastercard, Berkshire, Booking, Nike or Costco single-name items in the feed today. China’s cross-border digital-payments push remains a longer-run watch-item for the card networks, not a near-term catalyst.
Shelf single-names live today: none as standalone catalysts — the actionable read stays theme-level: durable AI-compute demand (semis/cloud) set against a hawkish-leaning Warsh Fed, an oil-relief FT says could take weeks, and a complacency flag in falling risk premia.
Net: the relief rally has substance — an actual deal and crude near a three-month low ease the stagflation tail — but FT’s caveats (Hormuz flows of weeks, economists betting on higher rates into Warsh’s Fed, risk being repriced too cheaply) keep the regime defensive-to-neutral. No severe trigger, so war-chest rules stay sheathed. Watch-lines: Wednesday’s Fed & dot plot, the Friday Hormuz signing/logistics, China stimulus signals, and AI-sector credit supply.
Markets snapshot
Read this morning from the live Bloomberg “Top Securities” ticker. Equity indices are Monday 15 June US/UK closes reflecting the deal rally; the 10-year, FX, crude and gold show the live overnight move. Asian cash markets are open and softer this morning on the BOJ hike and weak China data.
Instrument
Last
Move / context
S&P 500
7,554.29
+1.65% · Mon close; deal rally, semis lead
Nasdaq
26,683.94
+3.07% · Mon close; AI / SpaceX surge
Bloomberg 500
2,731.46
+1.74% · Mon close; broad risk-on
FTSE 100
10,430.62
+0.39% · Mon close; lags as oil unwinds
US 10-year Treasury
4.48%
yields a touch higher · rate-cut bets fade pre-Fed
EUR/USD
1.16
steady · dollar firm into the Fed
GBP/USD
1.34
steady · eyes Thursday’s BOE
Crude Oil (WTI)
$80.66
+0.11% · near 3-mo low; Hormuz reopening contested (flows ~weeks)
Gold (spot)
$4,353.30
+0.04% · holds gains near record
Levels transcribed from the Bloomberg Europe ticker this morning. Equities are Monday’s US/UK closes (the deal rally is now printed); crude, gold, the 10-year and FX reflect the live overnight move — oil hovering near a three-month low as the war premium drains slowly, gold firm near record, yields up a touch as rate-cut hopes fade. Next catalysts: Wednesday’s Warsh Fed, the G7, and the Friday Hormuz signing.
Global markets & macro
The war premium is unwinding on substance, and Monday’s US session showed it: the S&P 500 rose 1.65% to 7,554 and the Nasdaq 3.07% to 26,684, both at or near records, with semiconductors and a second-day SpaceX surge (+$412bn) driving the tape. But the follow-through is faltering this morning. The BOJ lifted rates to a 31-year-high 1.00% (7–1, Ueda absent) and signalled more normalisation, ending its bond-buying taper from April 2027; the yen pared early gains. More striking was China: May retail sales fell for the first time in over three years, fixed-asset investment slumped further and home prices dropped faster, sending property stocks back to pre-2024-stimulus lows and refiners cutting runs after crude imports plunged. Asian equities turned mixed-to-lower as a result. WTI steadied near $80 after Morgan Stanley trimmed its oil forecasts on the revived supply outlook, while Trump and European allies openly diverged on how quickly Hormuz can reopen — the largest tanker operator says weeks. Treasuries softened slightly, with the 10-year near 4.48% as rate-cut bets faded into Warsh’s first Fed.
Above the macro, the capital-markets story keeps rewriting the plumbing. Nvidia launched its first bond since 2021, seeking over $25bn and pulling ~$85bn of peak orders, the newest entry in an AI-sector borrowing frenzy; SpaceX’s record debut kept compounding, and FT reports the AI boom is minting private equity’s biggest-ever windfalls, with Bain set to bank ~$15bn on Kioxia. The paradox holds: this torrent of equity and credit supply is a confidence vote on the buildout, yet it drains liquidity from existing names and concentrates risk in private credit just as a record ~$8tn sits idle in money funds. In M&A, Murdoch’s Fox agreed to buy Roku for $22bn to chase cord-cutters, and Andrea Orcel’s long Commerzbank pursuit advanced — though FT calls his circuitous route unexpectedly costly. The cross-currents to respect: a hawkish-leaning Warsh Fed Wednesday, China’s stalling demand, and risk premia FT warns are being priced too cheaply for a still-dangerous world.
Geopolitics & world news
The Middle East still anchors the tape, but the direction is de-escalation with caveats. The US and Iran have an initial deal to extend the ceasefire 60 days, clear mines and reopen the Strait of Hormuz, with an official signing set for Friday 19 June in Switzerland; Trump says the strait reopens then and is said to be weighing a $300bn incentive fund for Tehran tied to performance. Yet the seams show: European allies doubt the reopening can be as fast or clean as Trump claims, shipowners want confidence before transiting, and Netanyahu faces a cross-spectrum domestic backlash that the deal let Iran survive with leverage intact. The diplomacy converges on the G7 at Évian (day 2), where Trump hailed the agreement while divisions over sequencing persisted. On the eastern front, the EU formally opened accession talks with Ukraine after Hungary’s new leadership dropped its veto, Moldova moving in tandem; the UK is set to unveil fresh Russia sanctions and Ukraine energy support, and the EU accused China of training Russian troops.
Elsewhere, politics and governance dominate. Hungary began unwinding the Orban system with term limits and clawback provisions; in Turkey, Erdogan’s crackdown widened beyond politicians to comedians, musicians and executives; and Switzerland’s rejection of a population cap still reverberates. On tech policy, the fallout from the US export order that froze Anthropic’s top models continues, with explainers probing what was blocked and why, while Europe’s AI champion Mistral was found more vulnerable to Russian disinformation than rivals. For the medical reader, the standout is public-health: Bloomberg reports Ebola cases in DR Congo have topped 800, with aid groups warning the outbreak may be larger than recorded — a live preparedness story amid stretched global health budgets. FT, separately, questions Palantir’s claimed NHS productivity gains, finding the improvement concentrated in a handful of hospitals.
Clinical desk · NEJM this week
For the medical reader
A genuinely heavy week for cardiology and metabolic medicine — two practice-changing positives, two instructive negatives, and a landmark first-in-human gene-editing readout. The results, not just the titles:
OPTIMAL — IVUS vs. angiography in unprotected left main PCI (neutral). In 806 patients across 28 European centres (Italy, Spain, UK), routine intravascular-ultrasound guidance did not beat angiography-guided PCI: the composite of death, MI, stroke or any revascularisation occurred in 33.7% of the IVUS arm vs. 30.9% with angiography (HR 1.11) over a median 2.9 years. With the two accompanying editorials asking whether IVUS is “always necessary,” the read-through is that an angiography-only strategy is defensible when experienced operators work in high-volume centres — tempering the recent drive to image every left main. Companion papers on angiography-derived FFR and angiography-based physiology point the same way: physiology/imaging add-ons help selectively, not universally.
AVANT-GUARD — pulsed-field ablation as first-line therapy for persistent AF (positive). Randomising 310 patients 2:1 to PFA vs. antiarrhythmic drugs, first-line ablation sharply cut treatment failure: freedom from recurrent atrial arrhythmia at 12 months was 56% with PFA vs. 30% on drugs (HR 0.46; 95% CI 0.33–0.65; p<0.001), with serious device/procedure events at 5.1% — comfortably under the 12% safety bar. A solid case for moving ablation ahead of drugs in persistent, not just paroxysmal, AF.
VERVE-102 (HEART-2) — in vivo base editing of PCSK9 (first-in-human). A single infusion of a base editor that permanently switches off hepatic PCSK9 was given to 35 patients with heterozygous familial hypercholesterolaemia or premature CAD. Mean PCSK9 fell 51–88% and LDL-C 9–62% across ascending doses — a 78 mg/dL absolute LDL drop at the top (1.0 mg/kg) dose — with no dose-limiting toxicity (mild-to-moderate infusion reactions, transient ALT rises) and effects durable beyond a year in those followed longest. A genuine “one-and-done” LDL therapy is moving from concept toward clinic.
SYNCHRONIZE-1 — survodutide once-weekly for obesity (positive; theme-relevant). The GLP-1/glucagon dual agonist — the incretin class your book tracks via Novo and Lilly — delivered 76-week mean weight loss of −12.2% (3.6 mg) and −13.0% (6.0 mg) vs. −5.4% on placebo (up to 16.6% on the efficacy estimand) in 725 adults without diabetes, with visceral fat down ~34% and liver fat ~63% and muscle largely preserved. A credible challenger in the obesity race, with particular pull in MASLD — one to watch for the competitive read on the GLP-1 leaders.
FIND-CKD — finerenone in non-diabetic CKD (positive). In >1,500 patients with non-diabetic CKD and albuminuria already on a RAS inhibitor, finerenone (10/20 mg) slowed eGFR decline over 32 months vs. placebo — extending the non-steroidal MRA’s benefit to a population with almost no disease-modifying options to date, and likely to push its label well beyond diabetic kidney disease.
SWiFT — prehospital whole blood in trauma (neutral). Across 10 English air-ambulance services, up to 2 units of prehospital whole blood did not beat standard component therapy: death or massive transfusion within 24 h occurred in 48.7% vs. 47.7% (adjusted RR 1.02; 95% CI 0.80–1.31; p=0.84), echoed by a parallel US type-O whole-blood trial — a sobering check on the whole-blood momentum of recent years.
Also in the issue: mavacamten in adolescents with obstructive HCM; 10-year outcomes of early surgery for asymptomatic aortic stenosis; a review of anticoagulation-reversal antidotes plus an apixaban-vs-rivaroxaban bleeding comparison in acute VTE; teclistamab and selpercatinib readouts in myeloma and RET-fusion NSCLC; a case of human H5N5 avian-influenza infection; and a pointed Perspective trio on the myth of race-as-biology and the hazards of race-based drug dosing.
Drawn from the NEJM current-issue and cardiology RSS feeds (issue dated 11 June 2026 plus ahead-of-print); trial numbers cross-checked against NEJM abstracts and ACC / Heart Rhythm 2026 coverage. Summarised, not reproduced verbatim; not clinical advice.
Today & week ahead (CET)
Tue 16BOJ hiked to 1.00% (done) — 31-year high, 7–1 vote, taper to end Apr 2027 · FOMC two-day meeting begins · US May housing starts · G7 day 2 at Évian · China May activity data (retail sales, FAI, home prices) all soft
Wed 17Fed decision & dot plot — Warsh’s first as chair; economists leaning hawkish, focus on his press conference · US May retail sales
Thu 18BOE decision — expected hold at 3.75% despite inflation anxiety · UK Makerfield by-election (Burnham/Starmer backdrop) · FT markets Q&A (Armstrong/Martin)
Fri 19US–Iran signing ceremony in Switzerland — Strait of Hormuz set to reopen; watch oil & tanker-backlog logistics